Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma

Am J Respir Crit Care Med. 2016 Jul 1;194(1):118-20. doi: 10.1164/rccm.201511-2224LE.

Authors

Christopher E Brightling¹, Lars H Nordenmark², Meena Jain³, Edward Piper⁴, Dewei She⁵, Martin Braddock⁴, Gene Colice⁶, Göran Tornling²

Affiliations

¹ 1 University of Leicester Leicester, United Kingdom.
² 2 AstraZeneca Mölndal, Sweden.
³ 3 MedImmune Cambridge, United Kingdom.
⁴ 4 AstraZeneca Cambridge, United Kingdom.
⁵ 5 MedImmune Gaithersburg, Maryland and.
⁶ 6 AstraZeneca Gaithersburg, Maryland.

PMID: 27367889
DOI: 10.1164/rccm.201511-2224LE

No abstract available

Publication types

Clinical Trial, Phase II
Randomized Controlled Trial

MeSH terms

Airway Remodeling / drug effects*
Antibodies, Monoclonal / therapeutic use*
Asthma / drug therapy*
Double-Blind Method
Female
Humans
Interleukin-13 / antagonists & inhibitors*
Male
Middle Aged
Treatment Outcome

Substances

Antibodies, Monoclonal
Interleukin-13
tralokinumab